Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
暂无分享,去创建一个
T. Pumarola | A. Antón | A. Moreno | F. Pérez-Villa | C. Cervera | C. Esteva | M. Marcos | M. Ricart | M. Navasa | F. Cofan | L. Linares | M. Pineda
[1] T. Pumarola,et al. Immunohistochemically proven cytomegalovirus end‐organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests , 2007, Transplant infectious disease : an official journal of the Transplantation Society.
[2] M. Schnitzler,et al. Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] Nina Singh,et al. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy , 2006, Reviews in medical virology.
[4] D. Snydman. The case for cytomegalovirus prophylaxis in solid organ transplantation , 2006, Reviews in medical virology.
[5] A. Limaye,et al. Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis , 2006, Transplantation.
[6] J. Pérez,et al. Recomendaciones GESITRA-SEIMC y RESITRA sobre prevención y tratamiento de la infección por citomegalovirus en pacientes trasplantados , 2005 .
[7] M. Pescovitz,et al. Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High‐risk CMV D+/R− Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[8] T. Popow-Kraupp,et al. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. , 2004, The Journal of infectious diseases.
[9] B. Alexander,et al. Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[10] S. Hossain,et al. Cytomegalovirus Disease in High‐Risk Transplant Recipients Despite Ganciclovir or Valganciclovir Prophylaxis , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[11] P. Griffiths,et al. Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] D. Schoenfeld,et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis , 2000, Transplant infectious disease : an official journal of the Transplantation Society.